WO2008045272A3 - Compositions and methods for skin lightening - Google Patents

Compositions and methods for skin lightening Download PDF

Info

Publication number
WO2008045272A3
WO2008045272A3 PCT/US2007/021288 US2007021288W WO2008045272A3 WO 2008045272 A3 WO2008045272 A3 WO 2008045272A3 US 2007021288 W US2007021288 W US 2007021288W WO 2008045272 A3 WO2008045272 A3 WO 2008045272A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
skin
compositions
mammal
skin lightening
Prior art date
Application number
PCT/US2007/021288
Other languages
French (fr)
Other versions
WO2008045272A2 (en
Inventor
Annette Tobia
Michael Schwartz
Alice Marcy
Original Assignee
Dynamis Therapeutics Inc
Annette Tobia
Michael Schwartz
Alice Marcy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynamis Therapeutics Inc, Annette Tobia, Michael Schwartz, Alice Marcy filed Critical Dynamis Therapeutics Inc
Publication of WO2008045272A2 publication Critical patent/WO2008045272A2/en
Publication of WO2008045272A3 publication Critical patent/WO2008045272A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to compounds and methods for inhibiting production and function of tyrosinase in the skin of a mammal. The invention further relates to compounds and methods for inhibiting darkening of the skin of a mammal, as well as lightening the skin of a mammal and reducing pigmentation in the skin of a mammal.
PCT/US2007/021288 2006-10-06 2007-10-04 Compositions and methods for skin lightening WO2008045272A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85023106P 2006-10-06 2006-10-06
US60/850,231 2006-10-06

Publications (2)

Publication Number Publication Date
WO2008045272A2 WO2008045272A2 (en) 2008-04-17
WO2008045272A3 true WO2008045272A3 (en) 2008-06-19

Family

ID=39283355

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/021288 WO2008045272A2 (en) 2006-10-06 2007-10-04 Compositions and methods for skin lightening

Country Status (2)

Country Link
TW (1) TW200817039A (en)
WO (1) WO2008045272A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104887389B (en) 2009-01-29 2017-06-23 弗赛特影像4股份有限公司 Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
EP2228050A1 (en) * 2009-03-09 2010-09-15 Marcel Cohen Use of gamma-aminobutyric acid as a depigmenting agent
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
PT2600812T (en) 2010-08-05 2021-11-09 Forsight Vision4 Inc Implantable therapeutic device
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
WO2012141255A1 (en) * 2011-04-12 2012-10-18 株式会社 資生堂 Skin lightening agent and melanin production inhibitor
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
FR2979237B1 (en) * 2011-08-23 2013-08-16 Oreal METHOD OF DEPIGMENTING THE SKIN
HRP20210676T1 (en) 2011-09-16 2021-05-28 Forsight Vision4, Inc. Fluid exchange apparatus
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
EP2950790A4 (en) 2012-08-09 2018-04-25 Dynamis Therapeutics, Inc. Methods for maintaining or improving health, well-being and/or a physiological function in a subject
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
ES2972168T3 (en) 2013-03-28 2024-06-11 Forsight Vision4 Inc Ophthalmic implant for administration of therapeutic substances
ES2803102T3 (en) 2014-07-15 2021-01-22 Forsight Vision4 Inc Eye implant delivery device
WO2016022750A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
WO2016077371A1 (en) 2014-11-10 2016-05-19 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
MX2018012021A (en) 2016-04-05 2019-01-24 Forsight Vision4 Inc Implantable ocular drug delivery devices.
AU2018372806B2 (en) 2017-11-21 2024-05-30 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
FR3123193A1 (en) 2021-05-28 2022-12-02 L'oreal Electroporation process for delivering a composition comprising at least one peptide of molecular weight ranging from 500 Da to 20 kDa
FR3123192B1 (en) 2021-05-28 2025-04-04 Oreal Electroporation method for delivering a composition comprising at least one hydroxy acid compound
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
DE102023135652A1 (en) * 2022-12-23 2024-07-04 Constructor University Bremen Ggmbh Process for the preparation of a stable composition comprising a phytogenic extract or pressed juice for the care and/or dyeing or bleaching of hair, wood or fabric

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6219575B1 (en) * 1998-10-23 2001-04-17 Babak Nemati Method and apparatus to enhance optical transparency of biological tissues
US6653315B2 (en) * 2001-10-15 2003-11-25 Schering Corporation Adenosine A2a receptor antagonists
US20040265252A1 (en) * 2003-04-11 2004-12-30 New York University Compounds stimulating and inhibiting melanin formation, and methods for screening these compounds
US20060110439A1 (en) * 2004-10-22 2006-05-25 Dynamis Therapeutics, Inc. Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6219575B1 (en) * 1998-10-23 2001-04-17 Babak Nemati Method and apparatus to enhance optical transparency of biological tissues
US6653315B2 (en) * 2001-10-15 2003-11-25 Schering Corporation Adenosine A2a receptor antagonists
US20040265252A1 (en) * 2003-04-11 2004-12-30 New York University Compounds stimulating and inhibiting melanin formation, and methods for screening these compounds
US20060110439A1 (en) * 2004-10-22 2006-05-25 Dynamis Therapeutics, Inc. Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATTILA ET AL.: "Effects of a Long-Term Dietary Xylitol Supplementation on Collagen Content and Fluorescence of the Skin in Aged Rats", GERONTOLOGY, vol. 51, no. 3, 2005, pages 166 - 169 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery

Also Published As

Publication number Publication date
TW200817039A (en) 2008-04-16
WO2008045272A2 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
WO2008045272A3 (en) Compositions and methods for skin lightening
WO2007093627A3 (en) Biocidal composition
WO2010005989A8 (en) Dermatological compositions with anti-aging and skin even-toning properties
EP4269578B8 (en) Soluble hyaluronidase composition
ZA201006732B (en) 2-aza-bicyclo[2.2.1]heptane derivatives
WO2009135857A3 (en) Polyurethanes as rheological modifying means for cosmetic preparations
WO2011059866A3 (en) Composition and methods for improving skin appearance
WO2008070616A3 (en) METHODS AND COMPOSITIONS RELATED TO HIF-1α
IL209188A0 (en) A sweetener, compositions comprising the same and methods of producing the same
WO2006136357A3 (en) Crystalline modifications to pyraclostrobin
WO2008017074A3 (en) Dyes and precursors and conjugates thereof
WO2010118866A8 (en) Trehalulose-containing composition, its preparation and use
IL213694A0 (en) Melanin production inhibitor compounds and compositions comprising the same
WO2009007532A3 (en) Use of a haemoglobin for the preparation of dressings and resulting dressings
WO2009051460A3 (en) Peptide coupled ascorbic acid derivatives
ZA200807944B (en) Skin lightening agents, compositions and methods
ZA200807945B (en) Skin lightening agents, compositions and methods
WO2007144521A3 (en) Cosmetic composition for topical use comprising wasabi
EP2303010A4 (en) A composition for improving skin condition and appearance
ZA201100108B (en) Skin lightening compositions comprising co2 extracts
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
EP2061493A4 (en) Compositions to reduce or prevent skin cancer
PL385075A1 (en) method of production of cement and hydraulic binding agent as well as the cement and hydraulic binding agent, and method to upgrade class of cement and application of cement
WO2010130776A3 (en) Use of delta-tocopheryl-carbohydrate as a depigmenting agent
WO2007133571A3 (en) Methods and compositions related to tr4

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07839230

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07839230

Country of ref document: EP

Kind code of ref document: A2